Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24101234 | 1.00 | SMN1; SMN2 (0.40) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL24393471 | 0.90 | MEN1 (0.39) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL22561334 | 0.88 | ADAMTS4 (0.41) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL20733348 | 0.88 | ADAMTS4 (0.41) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL15099992 | 0.88 | SMN1; SMN2 (0.48) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL12285446 | 0.86 | PLG (0.44) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL18494908 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9AGAAMEN1 | |
| SCHEMBL25993243 | 0.84 | NPC1 (0.43) | SMN1; SMN2NPC1RAB9ASPHK1MAPT | |
| SCHEMBL24279731 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL20258440 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1RAB9AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-11-09 | — | — | US | disclosed |
| US-20230233703-A1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230355792-A1 | METHODS OF IMPROVING THE THERAPEUTIC INDEX | CD47, ANXA5, MTX1 | SMN1; SMN2 1640/4885NPC1 2113/4885RAB9A 1307/4885 |
| US-20230233703-A1 | AMANITIN CONJUGATES | CD47, MTX1, SIGLEC7 | SMN1; SMN2 2480/4885NPC1 3747/4885RAB9A 1706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.